Trial record 1 of 33 for: Open Studies | "Helicobacter Infections"

Previous Study | Return to List | Next Study

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2008 by University of California, Los Angeles.
Recruitment status was Recruiting

Sponsor:

Collaborator:

Michael J. Fox Foundation for Parkinson's Research

Information provided by:

University of California, Los Angeles

ClinicalTrials.gov Identifier:

NCT00664209

First received: April 21, 2008

Last updated: NA

Last verified: April 2008

History: No changes posted

Purpose

The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.

Condition	Intervention	Phase
Parkinson's Disease Helicobacter Infections Motor Fluctuations	Drug: clartihromycin, amoxicillin, and omeprazole Drug: placebo	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Parkinson disease Perry syndrome

MedlinePlus related topics: Helicobacter Pylori Infections Parkinson's Disease

Drug Information available for: Amoxicillin Amoxicillin sodium Omeprazole Clarithromycin Omeprazole magnesium Esomeprazole Esomeprazole Sodium Esomeprazole magnesium

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:

Average total daily "off" time (measured by patient symptom diaries) [ Designated as safety issue: No ]

Secondary Outcome Measures:

Improvement in UPDRS total scores ("on" and "off") [ Designated as safety issue: No ]
Improvement in UDPRS Part III (Motor) scores ("on" and "off") [ Designated as safety issue: No ]
Improvement in quality of life measures (using PDQ-39)
Side effects profile [ Designated as safety issue: Yes ]

Estimated Enrollment:	100
Study Start Date:	January 2008

Arms	Assigned Interventions
Active-placebo These subject receive treatment with active triple therapy followed by treatment with placebo therapy.	Drug: clartihromycin, amoxicillin, and omeprazole clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days Other Name: Biaxin, Prilosec Drug: placebo placebo therapy
Placebo-active These subject receive treatment with placebo therapy followed by treatment with active triple therapy.	Drug: clartihromycin, amoxicillin, and omeprazole clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days Other Name: Biaxin, Prilosec Drug: placebo placebo therapy

Detailed Description:

Previous investigations have demonstrated that treatment of Helicobacter pylori with antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may potentially benefit patients with Parkinson's disease who have motor fluctuations, specifically excessive "off" time, when their levodopa is not working to control symptoms. We seek to identify the frequency of H. pylori infection in this population using standard lab assays and determine whether eradication with standard triple therapy results in improved clinical response to medication.

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Adults diagnosed with idiopathic Parkinson's disease, Hoehn & Yahr stage 2-4 in the "off" state, with no other concomitant neurologic diseases.
Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy, but with wearing off phenomenon present between levodopa doses (average off time ≥3 hours off time/day).
Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is acceptable. Parkinson's disease treatment may also include any of the following medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B inhibitors, amantadine, anticholinergics.
Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized treatment arms).

Exclusion criteria:

Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding.
History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal lesions.
History of previous gastric surgery.
History of previous brain surgery for Parkinson's disease.
Family history of gastric cancer.
Prior treatment for H. pylori+ status.
Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or clarithromycin.
Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole.
Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide).
Inability to tolerate or participate in testing in the morning in an "off" state.
Inability to communicate effectively with study personnel in English.
Pregnancy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00664209

Contacts

Contact: Nicholas R Szumski, MD

310-206-4144

nszumski@mednet.ucla.edu

Locations

United States, California
UCLA Neurology	Recruiting
Los Angeles, California, United States, 90095

Sponsors and Collaborators

University of California, Los Angeles

Michael J. Fox Foundation for Parkinson's Research

Investigators

Principal Investigator:

Jeff M Bronstein, MD, PhD

UCLA Neurology

More Information

Publications:

Belhoussine-Idrissi L, Boedeker EC. Helicobacter pylori infection: treatment. Curr Opin Gastroenterol. 2002 Jan;18(1):26-33.

Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006 Jun 27;66(12):1824-9.

Pierantozzi M, Pietroiusti A, Galante A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Stanzione P. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol. 2001 Nov;50(5):686-7. No abstract available.

Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol Sci. 2001 Feb;22(1):89-91.

Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21(2):315-24. Review.

Responsible Party:	Jeff Bronstein, MD, PhD, UCLA Neurology
ClinicalTrials.gov Identifier:	NCT00664209 History of Changes
Other Study ID Numbers:	MJJF Clinical Discovery 2007, 441437-JB-58330
Study First Received:	April 21, 2008
Last Updated:	April 21, 2008
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:

Parkinson's disease
levodopa
Helicobacter pylori

Additional relevant MeSH terms:

Helicobacter Infections
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Gram-Negative Bacterial Infections
Bacterial Infections

Amoxicillin
Omeprazole
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 16, 2013

To Top